Clinical trial

A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight…

NCT00404963 · GlaxoSmithKline, Industry · Completed

Key facts

NCT number NCT00404963
Title A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
Official title A Single-Blind, Randomized, Placebo Controlled, Ascending Single and Repeat Dose Study With Once Daily Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 and to Evaluate Food Effects and the Relative Bioavailability of a Tablet Formulation Compared to…
Lead sponsor GlaxoSmithKline, Industry
Status Completed
Phase Phase 1
Study type Interventional
Conditions Type 2 Diabetes Mellitus
Intervention type Drug
Interventions placebo, GSK376501
Enrollment 72
Start date Oct 1, 2006
Primary completion May 1, 2007
Completion May 1, 2007
First posted Nov 29, 2006
Last update posted Jan 19, 2017
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies